B+
Bull case
0%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
ADMA
ADMA BiologicsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition. ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Heavy reliance on ASCENIV growth leaves results sensitive to any slowdown in adoption or utilization. [#SEC-8K-2026-08-05]
Momentum
92
Value
65
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $15.00 · Bear $7.50Analysis 2026-10-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $18.67
Why
Momentum92 · Δ7d +7.8
Value65 · Δ7d +0.0
Sentiment67 · Δ7d +1.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Heavy reliance on ASCENIV growth leaves results sensitive to any slowdown in adoption or utilization. [#SEC-8K-2026-08-05]
- • Persistent competition and pricing pressure in the standard U.S. immune-globulin market are explicitly reflected in ADMA's 2026 outlook. [#SEC-8K-2026-08-05]
- • Total second-quarter revenue grew only 2% despite ASCENIV's 24% growth.
Catalyst clock
2026-11-30
ASCENIV real-world evidence at ACAAI
Lead driver: Value · See fundamentals
Momentum
92
8% active weight
Current posture
7d trendImproving
Δ7d
+7.8
Δ21d
+25.0
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-1.1
Sentiment
67
45% active weight
Current posture
7d trendFlat
Δ7d
+1.0
Δ21d
-13.4
Why this grade
Composite grade A. Momentum 92.3 / Value 65.1 / Sentiment 67.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$2.5B
Beta
0.49
Shares Out
223.99M
P/E (TTM)
21.3
P/S (TTM)
8.78
P/FCF (TTM)
105.67
Rev YoY
+2.0%
EPS YoY
+19.3%
Gross Margin
+64.7%
Op Margin
+42.3%
Net Debt
-$7.75M
Current Ratio
6.97
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data